Last updated August 8th 2017


August 3, 2017 | Israeli bio-pharmaceutical company Eloxx has raised $8 million in a Series C funding round led by LPS, a leading healthcare investor. Other investors such as Pontifax VC, Catalyst, KIP, DSC Funds, Dr. Phil Frost, OPKO Health Inc., and private investors also participated. This brings the company’s total equity to $38 million. The Herzliya company develops treatments for patients with rare genetic diseases triggered by mutations like Cystic Fibrosis and Cystinosis. Founded in 2013 by Dr. Silvia Noiman, Eloxx recently merged with Sevion Therapeutics and became a Sevion subsidiary. Sevion will use the name Eloxx and attempt to list its shares on Nasdaq.